NCT01097408

Pharmacokinetics of AZD7295 Capsules

A Randomised, Double-Blind, Placebo-Controlled Study to Determine the Pharmacokinetics, Safety and Tolerability of AZD7295 Capsules in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Arrow Therapeutics · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This is a pharmacokinetics (PK) and safety study of AZD7295 in healthy volunteers.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	AZD7295	Up to 650mg AZD7295 capsules per dose. To be given 2 or 3 times daily for 5 days.
DRUG	Placebo comparator	Placebo capsules

Timeline

• Start date: 2010-03-01
• Primary completion: 2010-05-01
• Completion: 2010-08-01
• First posted: 2010-04-01
• Last updated: 2010-08-09

Locations

1 site across 1 country: United Kingdom